Crispr Theraptc (CRSP) Receives Consensus Rating of “Buy” from Brokerages
Crispr Theraptc (NASDAQ:CRSP) has been assigned a consensus rating of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $21.60.
A number of research analysts have weighed in on CRSP shares. SunTrust Banks, Inc. started coverage on Crispr Theraptc in a report on Thursday, July 13th. They set a “hold” rating and a $16.00 target price for the company. Cann started coverage on Crispr Theraptc in a report on Monday, July 17th. They set a “market perform” rating for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Crispr Theraptc in a report on Monday, August 14th.
Shares of Crispr Theraptc (NASDAQ:CRSP) opened at 20.48 on Friday. The firm’s 50-day moving average is $18.17 and its 200-day moving average is $17.74. Crispr Theraptc has a 52 week low of $11.63 and a 52 week high of $25.00. The firm’s market capitalization is $831.30 million.
Crispr Theraptc (NASDAQ:CRSP) last posted its earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.06. The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $3.29 million. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The company’s revenue was up 350.0% compared to the same quarter last year. Equities analysts anticipate that Crispr Theraptc will post ($2.43) EPS for the current year.
In other news, CEO Rodger Novak sold 30,222 shares of the business’s stock in a transaction dated Wednesday, June 21st. The stock was sold at an average price of $15.01, for a total transaction of $453,632.22. Following the completion of the transaction, the chief executive officer now owns 1,230,397 shares of the company’s stock, valued at $18,468,258.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kurt Von Emster sold 32,368 shares of the business’s stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $16.23, for a total value of $525,332.64. The disclosure for this sale can be found here. Insiders have sold 814,754 shares of company stock valued at $14,759,468 in the last three months. 39.98% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of CRSP. Wellington Management Group LLP raised its position in shares of Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the last quarter. Monashee Investment Management LLC raised its position in shares of Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares during the last quarter. Paulson & CO. Inc. acquired a new position in shares of Crispr Theraptc during the first quarter valued at approximately $1,099,000. Credit Suisse AG acquired a new position in shares of Crispr Theraptc during the first quarter valued at approximately $1,742,000. Finally, IHT Wealth Management LLC acquired a new position in shares of Crispr Theraptc during the first quarter valued at approximately $110,000. 23.90% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/01/crispr-theraptc-crsp-receives-consensus-rating-of-buy-from-brokerages.html.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Stock Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related stocks with our FREE daily email newsletter.